The Ameliorating Effects of n-3 Polyunsaturated Fatty Acids on Liver Steatosis Induced by a High-Fat Methionine Choline-Deficient Diet in Mice

Int J Mol Sci. 2023 Dec 7;24(24):17226. doi: 10.3390/ijms242417226.

Abstract

The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is associated with abnormalities of liver lipid metabolism. On the contrary, a diet enriched with n-3 polyunsaturated fatty acids (n-3-PUFAs) has been reported to ameliorate the progression of NAFLD. The aim of our study was to investigate the impact of dietary n-3-PUFA enrichment on the development of NAFLD and liver lipidome. Mice were fed for 6 weeks either a high-fat methionine choline-deficient diet (MCD) or standard chow with or without n-3-PUFAs. Liver histology, serum biochemistry, detailed plasma and liver lipidomic analyses, and genome-wide transcriptome analysis were performed. Mice fed an MCD developed histopathological changes characteristic of NAFLD, and these changes were ameliorated with n-3-PUFAs. Simultaneously, n-3-PUFAs decreased serum triacylglycerol and cholesterol concentrations as well as ALT and AST activities. N-3-PUFAs decreased serum concentrations of saturated and monounsaturated free fatty acids (FAs), while increasing serum concentrations of long-chain PUFAs. Furthermore, in the liver, the MCD significantly increased the hepatic triacylglycerol content, while the administration of n-3-PUFAs eliminated this effect. Administration of n-3-PUFAs led to significant beneficial differences in gene expression within biosynthetic pathways of cholesterol, FAs, and pro-inflammatory cytokines (IL-1 and TNF-α). To conclude, n-3-PUFA supplementation appears to represent a promising nutraceutical approach for the restoration of abnormalities in liver lipid metabolism and the prevention and treatment of NAFLD.

Keywords: lipidome; lipids; n-3 fatty acids; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis.

MeSH terms

  • Animals
  • Cholesterol / metabolism
  • Choline / metabolism
  • Diet, High-Fat / adverse effects
  • Fatty Acids, Nonesterified / metabolism
  • Fatty Acids, Omega-3* / metabolism
  • Fatty Acids, Omega-3* / pharmacology
  • Fatty Acids, Omega-3* / therapeutic use
  • Fatty Acids, Unsaturated / metabolism
  • Liver / metabolism
  • Methionine / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease* / etiology
  • Non-alcoholic Fatty Liver Disease* / genetics
  • Racemethionine / metabolism
  • Racemethionine / pharmacology
  • Triglycerides / metabolism

Substances

  • Fatty Acids, Omega-3
  • Methionine
  • Choline
  • Fatty Acids, Unsaturated
  • Racemethionine
  • Fatty Acids, Nonesterified
  • Cholesterol
  • Triglycerides